Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors

被引:0
作者
William H. Ludlam
Lowell Anthony
机构
[1] Swedish Neuroscience Institute,Seattle Pituitary Center
[2] University of Kentucky,Markey Cancer Center
来源
Advances in Therapy | 2011年 / 28卷
关键词
acromegaly; dose optimization; lanreotide; neuroendocrine tumors; octreotide; safety; somatostatin analogs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:825 / 841
页数:16
相关论文
共 185 条
[1]  
Modlin I.M.(2006)Therapeutic options for gastrointestinal carcinoids Clin Gastroenterol Hepatol 4 526-547
[2]  
Latich I.(2006)Quality of life in acromegaly Neuroendocrinology 83 224-229
[3]  
Kidd M.(2009)Guidelines for acromegaly management: an update J Clin Endocrinol Metab 94 1509-1517
[4]  
Zikusoka M.(2010)Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours Acta Oncol 49 740-756
[5]  
Eick G.(2009)From somatostatin to octreotide LAR: evolution of a somatostatin analogue Curr Med Res Opin 25 2989-2999
[6]  
Webb S.M.(1982)SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1133-1140
[7]  
Melmed S.(2005)Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors Mayo Clin Proc 80 502-506
[8]  
Colao A.(2008)Pasireotide (SOM230): development, mechanism of action and potential applications Mol Cell Endocrinol 286 69-74
[9]  
Barkan A.(2005)Consensus statement: medical management of acromegaly Eur J Endocrinol 153 737-740
[10]  
Janson E.T.(2004)Neuroendocrine tumors Ann Oncol 15 iv293-iv2989